Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 76.47% is 119% above its 5-year average of -396.36%, near the high end of its 5-year range (-1098.27%–228.64%).
156.31% above its 12-month average of -135.79%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
76.47%
GROSS MARGIN AVG TTM
-135.79%
GROSS MARGIN AVG 3Y
-213.04%
GROSS MARGIN AVG 5Y
-396.36%
GROSS MARGIN AVG 10Y
-291.36%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+156.31%
CURRENT VS 3Y AVG
+135.89%
CURRENT VS 5Y AVG
+119.29%
CURRENT VS 10Y AVG
+126.25%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
59.92%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+27.61%
vs the sector median at left
Intellia Therapeutics, Inc.
Market Cap
$1.72B
Gross Margin
76.47%
TTM Avg
-135.79%
3Y Avg
-213.04%
5Y Avg
-396.36%
Market Cap
$1.73B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
Market Cap
$2.14B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$1.00B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$2.51B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
Market Cap
$2.74B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$472.39M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
Market Cap
$397.55M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | $1.72B | 76.47% | -135.79% | -213.04% | -396.36% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 49.52% | 50.81% | 52.12% | 52.25% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -61.96% | -19.42% | -14.39% | 23.74% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 73.53% | 70.13% | 70.04% | 68.74% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | 84.05% | -197.31% | -176.53% | -71811.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 58.69% | 59.64% | 63.22% | 64.62% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | 42.92% | 41.39% | 40.24% | 40.24% |
| NRC Health (NRC)vs › | $459.30M | 56.33% | 58.27% | 60.30% | 61.48% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | 77.34% | 76.74% | 77.57% | 77.57% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
76.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 85.37% |
| 2025-12-31 | 73.87% |
| 2025-09-30 | -472.84% |
| 2025-06-30 | -465.34% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | -807.85% |
| 2024-09-30 | -1098.27% |
| 2024-06-30 | 62.64% |
| 2024-03-31 | 91.32% |
| 2023-12-31 | 228.64% |
| 2023-09-30 | 80.90% |
| 2023-06-30 | -747.99% |
| 2023-03-31 | -670.40% |
| 2022-12-31 | -637.01% |
| 2022-09-30 | -628.56% |
| 2022-06-30 | -542.90% |
| 2022-03-31 | -1082.86% |
| 2021-12-31 | -453.61% |
| 2021-09-30 | -739.62% |
| 2021-06-30 | -798.99% |
| 2021-03-31 | -509.40% |
| 2020-12-31 | -479.70% |
| 2020-09-30 | -78.92% |
| 2020-06-30 | -132.25% |
| 2020-03-31 | -168.27% |
| 2019-12-31 | -190.15% |
| 2019-09-30 | -159.17% |
| 2019-06-30 | -129.00% |
| 2019-03-31 | -127.25% |
| 2018-12-31 | -152.77% |
| 2018-09-30 | -213.67% |
| 2018-06-30 | -205.68% |
| 2018-03-31 | -201.15% |
| 2017-12-31 | -217.49% |
| 2017-09-30 | -138.91% |
| 2017-06-30 | -163.06% |
| 2017-03-31 | -116.11% |
| 2016-12-31 | -101.37% |
| 2016-09-30 | -61.45% |
| 2016-06-30 | -76.49% |
| 2016-03-31 | -194.03% |
| 2015-12-31 | -158.42% |
| 2015-09-30 | -104.86% |
| 2015-06-30 | -42.77% |
| 2015-03-31 | -6.61% |
| 2014-12-31 | 0.00% |
| 2014-06-30 | 0.00% |
